Questions to the Committee Tobacco Products Scientific Advisory Committee Meeting April 6, 2017

In relation to meeting preparation:

1.	How was the information provided to the TPSAC prior to the 2015 meeting on the MRTPAs for the SMNA snus products helpful in preparing for the meeting?
2.	How do you anticipate preparing for upcoming application review TPSAC meetings?
3.	What information would be most useful to receive prior to an application review TPSAC meeting?
4.	What information would likely be least useful prior to an application review TPSAC meeting?
5.	How would having only an Executive Summary or only the sections of the application that FDA planned to discuss, compared to having the entire application, impact your ability to prepare for an application review TPSAC meeting and give advice to FDA?
In relation to the meeting itself:	
6.	How was the information provided during the presentations at the 2015 meeting on the MRTPAs for the SMNA snus products helpful in providing advice to FDA?
7.	What information would be useful as part of the meeting presentations during an application review TPSAC meeting?
8.	What information would not be useful as part of the meeting presentations during

9. How might the TPSAC meeting be structured so that the committee is best positioned to provide advice to FDA?